J 811
Latest Information Update: 23 Mar 2007
Price :
$50 *
At a glance
- Originator Jenapharm
- Class Antihyperlipidaemics
- Mechanism of Action Antioxidants; Estrogen receptor agonists; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Menopausal syndrome
Most Recent Events
- 20 May 2003 Preclinical trials in Menopausal syndrome in Germany (unspecified route)